SAN FRANCISCO -- Neoadjuvant chemoimmunotherapy for muscle-invasive bladder cancer (MIBC) followed by risk-adapted therapy led to high rates of metastasis-free survival (MFS) and bladder preservation, ...
From a biomarker-driven strategy to delay or avoid cystectomy, to practice-changing perioperative immunotherapy, developments in bladder cancer frequently have made news over the past 12 months. The ...
Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...
Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...
Use of multiparametric MRI for the initial staging of suspected MIBC shortened the time to correct treatment compared with TURBT. Incorporating multiparametric MRI (mpMRI) into the initial staging of ...
Partial cystectomy for muscle-invasive bladder cancer offers metastasis- and cancer-free survival comparable to that of radical cystectomy, but with less perioperative morbidity. Partial and radical ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s IMFINZI ® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after ...
Urothelial carcinoma is cancer of the urinary system. The urothelium is a kind of epithelial (protective) lining of the urinary system, which includes the urinary tract, bladder, your ureters (the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback